ORLANDO Fla., May 21, 2019 — (CEOLIVE) In its latest update to stockholders, Hemispherx Biopharma proves it is on track for success with multiple clinical trials and successful fundraising during the first quarter.
Hemispherx (NYSEMKT:HEB) is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases.
The company has five ongoing clinical trials, including a 45-patient clinical study in ovarian cancer at University of Pittsburgh Medical Center combining Ampligen, cisplatin and pembrolizumab; a 12-patient clinical study in colorectal cancer at Roswell Park Comprehensive Cancer Center combining Ampligen, Intron A, and celecoxib; and a 6-patient clinical study in triple negative breast cancer at Roswell Park Comprehensive Cancer Center combining with Ampligen, Intron A, celecoxib and pembrolizumab. Hemispherx also recently extended the Early Access Program (EAP) at the Erasmus Medical Center in the Netherlands. For a more detailed update on the company’s cancer clinical trials, please see their most recent quarterly update.
CEOLIVE has been following Hemispherx Biopharma for the last two years and the company is now focusing its efforts on Ampligen’s potential in immuno-oncology.
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes drastic changes over the next decade, according to researchers. There are few if any other pharmaceutical companies with a comparable market cap that have a similar level of clinical study activity and their own drug-manufacturing capabilities.
Hemispherx Biopharma is a great turnaround story. The last 18 months have seen a number of significant new milestones and the company continues to deliver amazing progress on all fronts. We highly recommend keeping Hemispherx Biopharma on your radar as we think it represents an undervalued opportunity in the pharma space.
To see our most recent interview with CEO Thomas Equels, please visit: http://CEOLIVE.tv/hemispherx-biopharma-heb-showing-strong-progress-in-clinical-trials/
CEOLIVE.tv is committed to providing our readers with useful information on publicly traded companies. The CEOLIVE.tv sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinions about the company and the trading market for their securities. Specifically, Hemispherx subscribes to CEO Roadshow under a monthly contract pursuant to which it compensates CEOLIVE for investor relations and marketing services. Principals of the CEOLIVE.tv may also purchase or sell securities of the companies in the open market from time to time. The positions that the CEOLIVE.tv or its principals maintain in securities of the companies are disclosed at CEOLIVE.tv/disclosures and should be considered when making an investment decision regarding companies mentioned on CEOLIVE.tv. CEOLIVE.tv may be deemed to have a conflict of interest between its open market activity and positions in these securities and the timing of and opinions expressed in its publications concerning these companies. The publications should not be considered to be independent publications concerning the company.
It is also important to note, the CEOLIVE.tv is not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission or with any state securities regulatory authority. All statements and opinions expressed herein are those of the editors and contributors of CEOLIVE.tv and are subject to change without notice. The CEOLIVE.tv
maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. A profile, description, or other mention of a company at CEOLIVE.tv is neither an offer nor solicitation of an offer to buy or sell any securities mentioned. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties. Furthermore, CEOLIVE.tv has not independently verified such information provided within our publication.
Stock market investing is inherently risky. CEOLIVE is not responsible for any gains or losses that result from the opinions expressed in video productions, interviews, company profiles or in any other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission (“SEC”) at www.sec.gov or other applicable regulatory authorities.